SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WTDEC who wrote (384)11/21/1999 12:14:00 AM
From: Vector1  Read Replies (1) of 666
 
Great discussion. This is SI at its best.
My view of the data is that Bex has a slightly better side effect profile. Efficacy is very close. We do not yet have data from CLTR's study on patients who have failed Rit which will give a closer comparison to the recent Zev study. With regard to efficacy Bex appears to have an edge on length of remission. However to date Rit plus CHOP is the single most compelling study IMO. The early Bex plus Fludar is very promising with the combo resulting in a high percentage of CRs. We will have to see further data to see how long these responses last and whether there are any PCR CRs. Of note by pretreating with Fludar there were NO HAMA responses in first line patients. Ask yourself if you had this incideous disease which treatment would you choose. Tough call between CHOP plus Rit or Fludar plus Bex. There are many oncologists who are very comfortable with Fludar in first line treatment of NHL. The Fludar/Bex trial has the potential to defeat the argument that Bex is only a salvage treatment.
With regard to the question of whether CLTR is downplaying the side effect profile of Bex I simply do not beleive it. Bex is well supported by some of the top clinicians treating this disease at some of the nations most prestigeous cancer centers.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News